Skip to content

ESLA

Estrella Immunopharma, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.34
−19.84%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
+18.9%
EBIT
+18.9%
EPS
+25.4%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+36.9%
EPS
-41.4%

Three-year CAGR

Revenue
—
EBITDA
-47.7%
EBIT
-47.7%
Net income
-47.6%
EPS
-45.8%
Free cash flow
+42.6%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026